BRY 10
Alternative Names: BRY-10Latest Information Update: 17 Mar 2025
At a glance
- Originator Chugai Pharmaceutical
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 24 Sep 2024 Phase-I clinical trials in Unspecified in Japan (SC) (jRCT2051240123)